Latest news
July 12, 2024

Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12...

July 10, 2024

AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of...

July 02, 2024

AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at...

More »

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.

Advanced Search
Show 5102550100 per page
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2022 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2023 Annual Report on Form 10-K. Learn more



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?